{"filings":[{"id":96115,"accession_number":"0001213900-26-051681","cik":1841330,"company_name":"Pasithea Therapeutics Corp.","ticker":"KTTA","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Pasithea Therapeutics appoints Kartik Krishnan as Chief Medical Officer, effective May 1, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Krishnan appointed CMO effective May 1; will lead PAS-004 clinical strategy for NF1-associated neurofibromas.","Over 20 years of experience; previously CMO at Arcus Biosciences, contributed to cobimetinib approval for melanoma.","Employment agreement: $500k base salary, 40% bonus eligibility, and options for 1.13M shares at $0.841 exercise price.","CEO Tiago Reis Marques granted options for 1.76M shares; other execs/employees received 1.24M shares in aggregate.","Non-employee directors each receive options for 152,783 shares, vesting over one year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":23152871.95162476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109727,"accession_number":"0001213900-26-018874","cik":1841330,"company_name":"Pasithea Therapeutics Corp.","ticker":"KTTA","form_type":"8-K","filed_at":"2026-02-20T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Pasithea receives Nasdaq bid price deficiency notice; 180-day cure period","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Feb 20, 2026 for failing minimum $1.00 bid price for 30 consecutive business days.","Company has until August 19, 2026 to regain compliance; needs closing bid >=$1.00 for 10 consecutive days.","If not cured, may qualify for additional 180 days if it meets other listing standards and considers reverse split.","Notice does not affect business operations or SEC reporting; company evaluating options to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":23152871.95162476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109726,"accession_number":"0001213900-26-008828","cik":1841330,"company_name":"Pasithea Therapeutics Corp.","ticker":"KTTA","form_type":"8-K","filed_at":"2026-01-28T23:59:59+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"Pasithea stockholders approve 5x increase in authorized common stock and 7x expansion of incentive plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common stock increased from 100M to 500M shares via certificate amendment filed Jan 28, 2026.","2023 Stock Incentive Plan share reserve raised from 2,014,221 to 14,000,000 shares (increase of 11,985,779).","Proposal 1 (share increase) passed with 16,066,757 votes for vs 647,972 against; Proposal 2 passed with 8,168,126 for vs 4,550,855 against.","Board adopted plan amendment on Dec 18, 2025; stockholder approval obtained at Jan 28, 2026 special meeting.","Expanded authorized shares and equity plan provide flexibility for future capital raising and employee incentives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":23152871.95162476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126256,"accession_number":"0001213900-25-121466","cik":1841330,"company_name":"Pasithea Therapeutics Corp.","ticker":"KTTA","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Pasithea Therapeutics regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency notice on June 23, 2025 for failing $1.00 minimum bid price rule 5550(a)(2).","Compliance deadline was December 22, 2025; on December 12, 2025 Nasdaq confirmed compliance.","Common stock (KTTA) maintained closing bid at or above $1.00 for sufficient consecutive business days.","Nasdaq notified company that the bid price deficiency matter is now closed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":23152871.95162476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126255,"accession_number":"0001213900-25-116985","cik":1841330,"company_name":"Pasithea Therapeutics Corp.","ticker":"KTTA","form_type":"8-K","filed_at":"2025-12-02T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Pasithea raises ~$60M in public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $60.0M; net proceeds of ~$54.9M after fees and expenses.","Offering priced at $0.75 per share/warrant; 80M shares (or pre-funded warrants) sold.","Led by healthcare investors including Vivo Capital, Janus Henderson, Coastlands Capital.","Insiders (CEO, CFO, board members) bought 400k shares at same price.","Cash runway extended through at least first half 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":23152871.95162476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126254,"accession_number":"0001213900-25-114763","cik":1841330,"company_name":"Pasithea Therapeutics Corp.","ticker":"KTTA","form_type":"8-K","filed_at":"2025-11-25T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Pasithea reports Phase 1 partial response for PAS-004 in advanced cancer; ALS Association awards $1M grant","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BRAF V600E melanoma patient achieved -31.9% tumor reduction on PAS-004 monotherapy; remains on trial >11 months.","Overall disease control rate 71.4% in BRAF-mutated tumors; no DLTs or discontinuations across 27 patients.","PAS-004 tablet formulation shows 3-fold higher dose-normalized exposure vs capsule with less variability.","Cohort 7 (37mg capsule): zero TRAEs in DLT period; 80% pERK inhibition at Cmax; SRC clears escalation to 45mg.","ALS Association awards ~$1M grant for Phase 1 study of PAS-004 in 12 ALS patients (safety, ALSFRS-R, NfL)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":23152871.95162476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126253,"accession_number":"0001213900-25-105599","cik":1841330,"company_name":"Pasithea Therapeutics Corp.","ticker":"KTTA","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Pasithea activates UAB site for Phase 1/1b PAS-004 NF1 trial; platinum sponsor of symposium","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New U.S. clinical site at University of Alabama at Birmingham activated for ongoing Phase 1/1b PAS-004 trial in adult NF1 patients; enrollment starts immediately.","PAS-004 is a next-generation macrocyclic oral MEK inhibitor being studied for symptomatic, inoperable plexiform neurofibromas.","Pasithea named Platinum Sponsor of the 2025 NF Caregivers Symposium at UAB on November 8, 2025.","CEO Tiago Reis Marques highlighted UAB's deep NF1 expertise and commitment to advancing care."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":23152871.95162476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126252,"accession_number":"0001213900-25-102673","cik":1841330,"company_name":"Pasithea Therapeutics Corp.","ticker":"KTTA","form_type":"8-K","filed_at":"2025-10-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Pasithea Therapeutics approves new executive/director compensation and option grants at $0.715","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Tiago Reis Marques base salary increased to $533,000; target bonus reduced to 55%.","CFO Daniel Schneiderman base salary increased to $391,000; target bonus at 40%.","Stock options granted: CEO 493,341 shares, CFO 317,266, employees 352,266 total.","Board Chair annual cash compensation reduced from $100K to $35K; consulting fees cut to $1/quarter.","Non-employee directors each receive 42,913 share options; Prof. Steinman gets one-time 200,000 share option."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":23152871.95162476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143003,"accession_number":"0001213900-25-087903","cik":1841330,"company_name":"Pasithea Therapeutics Corp.","ticker":"KTTA","form_type":"8-K","filed_at":"2025-09-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Pasithea activates two South Korean sites for PAS-004 NF1 trial; first patient dosed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Two sites activated: Asan Medical Centre and Severance Hospital Yonsei University Health System, both now recruiting.","First patient in South Korea dosed; trial enrolling Cohort 2 (8 mg tablet) after SRC cleared Cohort 1 without modification.","Initial interim clinical data from first two cohorts expected in Q1 2026.","Phase 1/1b study of PAS-004 (macrocyclic MEK inhibitor) in adult NF1 patients with symptomatic plexiform neurofibromas.","Trial also includes sites in Australia and U.S.; Part A dose escalation (4 mg to 18 mg) identifying recommended Part B dose."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":23152871.95162476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143002,"accession_number":"0001213900-25-084062","cik":1841330,"company_name":"Pasithea Therapeutics Corp.","ticker":"KTTA","form_type":"8-K","filed_at":"2025-09-03T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Pasithea shareholders approve reverse split authorization (1:2–1:20) and 1.75M share increase for equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved reverse stock split of common stock at ratio from 1:2 to 1:20, at Board discretion, valid through September 2026.","Shareholders approved amendment to 2023 Stock Incentive Plan, increasing authorized shares by 1.75M to 2,014,221 shares.","Ratified CBIZ CPAs P.C. as independent auditor for FY2025 with 3.40M for, 39K against, 52K abstain.","Re-elected Alfred Novak (1.31M for) and Simon Dumesnil (1.29M for) as Class II directors, terms expiring 2028.","Quorum of 3.5M of 7.4M outstanding shares represented at the meeting; no other business."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":23152871.95162476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143001,"accession_number":"0001213900-25-063277","cik":1841330,"company_name":"Pasithea Therapeutics Corp.","ticker":"KTTA","form_type":"8-K","filed_at":"2025-07-11T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"Pasithea Therapeutics sets 2025 annual meeting for Sep 3; proposal deadline Jul 21","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting set for September 3, 2025; proxy materials expected available July 24, 2025.","Stockholder proposals under Rule 14a-8 must be received by July 21, 2025.","Universal proxy rule notice for director nominations also due by July 21, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":23152871.95162476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161075,"accession_number":"0001213900-25-059004","cik":1841330,"company_name":"Pasithea Therapeutics Corp.","ticker":"KTTA","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Pasithea Therapeutics receives Nasdaq minimum bid price non-compliance notice","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified company on June 23, 2025 that common stock bid price closed below $1.00 for 30 consecutive business days.","Company has 180 calendar days, until December 22, 2025, to regain compliance by closing at $1.00+ for 10 consecutive days.","If not cured, company may qualify for an additional 180-day period if it meets other listing requirements and intends to effect a reverse stock split.","Company is evaluating options; notice does not affect business operations or SEC reporting obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":23152871.95162476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161074,"accession_number":"0001213900-25-056209","cik":1841330,"company_name":"Pasithea Therapeutics Corp.","ticker":"KTTA","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pasithea Therapeutics upsizes ATM offering from $2.08M to $4.23M, adding $2.15M in new shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Maximum aggregate offering price increased from $2,076,000 to $4,227,000 under November 2024 Sales Agreement with H.C. Wainwright.","Current Prospectus Supplement filed June 20, 2025, registering an additional $2,151,000 of common stock.","Approximately $2,075,688 in shares already sold under the prior ATM limit, nearly exhausting previous capacity.","Proceeds intended for general corporate purposes; dilution impact on existing shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":23152871.95162476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161073,"accession_number":"0001213900-25-040725","cik":1841330,"company_name":"Pasithea Therapeutics Corp.","ticker":"KTTA","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Pasithea closes $5M public offering, receives $1.3M from warrant exercises","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offered 3,571,428 units at $1.40/unit (common stock or pre-funded warrant + Series C/D warrants); gross $5M.","Additional $1.3M from exercise of 914,286 Series D warrants at closing; total gross proceeds $6.3M.","Net proceeds ~$4.3M after fees and expenses; intended for R&D, clinical trials, and general corporate.","H.C. Wainwright acted as exclusive placement agent; 7% cash fee plus warrants for 250,000 shares at $1.75.","90-day lockup on further equity issuance; one-year restriction on variable rate transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":23152871.95162476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161072,"accession_number":"0001213900-25-035640","cik":1841330,"company_name":"Pasithea Therapeutics Corp.","ticker":"KTTA","form_type":"8-K","filed_at":"2025-04-25T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Pasithea Therapeutics dismisses Marcum, engages CBIZ as new auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum LLP dismissed as auditor Apr 23, 2025; CBIZ CPAs P.C. engaged for FY2025.","Change follows CBIZ's acquisition of Marcum's attest business effective Nov 1, 2024.","No accounting disagreements; only reportable event was a remediated tax provision material weakness.","Marcum's reports for FY2023 and FY2024 included going concern emphasis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":23152871.95162476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195939,"accession_number":"0001213900-24-102903","cik":1841330,"company_name":"Pasithea Therapeutics Corp.","ticker":"KTTA","form_type":"8-K","filed_at":"2024-11-26T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Pasithea enters $2.08M ATM equity facility with H.C. Wainwright","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATM agreement with H.C. Wainwright for up to $2,076,000 in common stock sales.","Sales agent commission: 3% of gross proceeds; company reimburses up to $100k in legal fees.","No minimum obligation; company may suspend or terminate the offering at any time.","Sales will be made on Nasdaq as 'at the market' offerings per Rule 415."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":23152871.95162476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212216,"accession_number":"0001213900-24-083408","cik":1841330,"company_name":"Pasithea Therapeutics Corp.","ticker":"KTTA","form_type":"8-K","filed_at":"2024-09-30T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Pasithea Therapeutics raises $5M in private placement of pre-funded warrants and Series A/B warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$5M; net proceeds ~$4.5M after fees and expenses.","Issued 1,219,513 pre-funded warrants at $0.001 exercise, plus Series A and B warrants at $3.85 exercise; combined price $4.099 per unit.","Series A warrants expire in 5 years, Series B warrants expire in 18 months.","Proceeds for working capital and general corporate purposes; H.C. Wainwright acted as placement agent.","Company agreed to file resale registration statement within 15 days; 90-day lock-up on further equity issuance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":23152871.95162476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212215,"accession_number":"0001213900-24-081982","cik":1841330,"company_name":"Pasithea Therapeutics Corp.","ticker":"KTTA","form_type":"8-K","filed_at":"2024-09-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Pasithea reports positive Phase 1 data for PAS-004: no TRAEs, prolonged stable disease in colon cancer patient","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["No treatment-related adverse events or dose-limiting toxicities observed in first 2 cohorts (n=6); no rash or GI toxicity.","Heavily pre-treated stage 3 colon cancer patient (BRAF K601E) achieved prolonged stable disease, remains on drug into 6th cycle.","Half-life ~70 hours supports once-daily or less frequent oral dosing; steady-state Cmax/Cmin ratio of 1.2.","Systemic exposure at steady-state enables constant target inhibition while avoiding peak plasma toxicities.","Safety review completed; cohort 3 dosing initiated at 8 mg with protocol amendment to increase dosing schedule."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":23152871.95162476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231127,"accession_number":"0001213900-24-056205","cik":1841330,"company_name":"Pasithea Therapeutics Corp.","ticker":"KTTA","form_type":"8-K","filed_at":"2024-06-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Pasithea Therapeutics stockholders elect Dr. Emer Leahy as Class I director; ratify Marcum LLP as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Dr. Emer Leahy elected as Class I director with 227,198 for, 27,223 withheld, 115,196 broker non-votes.","Ratification of Marcum LLP as independent auditor approved: 333,986 for, 34,177 against, 1,454 abstain.","Annual Meeting held June 26, 2024; quorum of 369,617 shares of 1,043,248 outstanding shares represented."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":23152871.95162476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231126,"accession_number":"0001213900-24-043036","cik":1841330,"company_name":"Pasithea Therapeutics Corp.","ticker":"KTTA","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"Pasithea Therapeutics schedules 2024 Annual Meeting for June 26, 2024; sets May 24 shareholder proposal deadline.","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting via internet on June 26, 2024 at 9:00 a.m. ET; record date April 29, 2024.","Deadline for Rule 14a-8 shareholder proposals for proxy inclusion is May 24, 2024.","Proposals must be mailed to company's Miami Beach, FL address.","No other material updates in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":23152871.95162476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249509,"accession_number":"0001213900-24-004520","cik":1841330,"company_name":"Pasithea Therapeutics Corp.","ticker":"KTTA","form_type":"8-K","filed_at":"2024-01-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Pasithea regains Nasdaq minimum bid price compliance, delisting risk removed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on Jan 17, 2024 confirming compliance with $1.00 minimum bid price rule.","Stock held closing bid at or above $1.00 for sufficient consecutive business days to satisfy requirement.","Previously received non-compliance notice on Jan 19, 2023 and extension to Jan 15, 2024.","Matter is now closed; no further action needed regarding bid price deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":23152871.95162476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249508,"accession_number":"0001213900-24-000296","cik":1841330,"company_name":"Pasithea Therapeutics Corp.","ticker":"KTTA","form_type":"8-K","filed_at":"2024-01-02T23:59:59+00:00","items":["3.03","5.03","5.07","9.01"],"status":"ready","headline":"Pasithea shareholders approve classified board, supermajority vote, eliminate written consent","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved classifying Board into three classes with staggered 3-year terms; removal only for cause.","Approved elimination of stockholder ability to act by written consent and to call special meetings.","Approved requirement of 66 2/3% vote to amend Bylaws; vote results: 10,473,072 for, 1,513,065 against.","Certificate restated to include officer exculpation and other governance changes; effective Dec 29, 2023.","Clerical filing corrected reverse stock split (1:20) to be an amendment to the Restated Certificate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":23152871.95162476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266966,"accession_number":"0001213900-23-099115","cik":1841330,"company_name":"Pasithea Therapeutics Corp.","ticker":"KTTA","form_type":"8-K","filed_at":"2023-12-28T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Pasithea Therapeutics announces 1-for-20 reverse stock split effective January 2, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio of 1-for-20; authorized shares reduced from 495M to 100M.","Effective at market open on January 2, 2024; CUSIP changes to 70261F202.","No fractional shares issued; cash payment based on 5-day average closing price pre-split.","All outstanding options, warrants, and convertible debt adjusted proportionately.","Board approved the split on Dec 21; shareholders authorized at Dec 19 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":23152871.95162476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266965,"accession_number":"0001213900-23-097013","cik":1841330,"company_name":"Pasithea Therapeutics Corp.","ticker":"KTTA","form_type":"8-K","filed_at":"2023-12-19T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Pasithea shareholders approve 2023 equity plan and reverse split authorization","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved Pasithea 2023 Stock Incentive Plan: 2.5M shares reserved plus rollover of unused 2021 plan shares.","Reverse stock split authorized (1:2 to 1:20) at Board discretion within one year; corresponding reduction in authorized shares allowed.","All five director nominees elected: Dr. Tiago Reis Marques, Prof. Lawrence Steinman, Simon Dumesnil, Dr. Emer Leahy, Alfred Novak.","Marcum LLP ratified as independent auditor for FY 2023; annual meeting partially adjourned to Dec. 28 for additional governance proposals.","Proxies remain open only for adjourned proposals (charter amendment, classified board, written consent restrictions)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":23152871.95162476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266964,"accession_number":"0001013762-23-003856","cik":1841330,"company_name":"Pasithea Therapeutics Corp.","ticker":"KTTA","form_type":"8-K","filed_at":"2023-10-13T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"Pasithea Therapeutics sets 2023 annual meeting for Nov 29; shareholder proposal deadline Oct 23","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual meeting set for November 29, 2023; proxy materials to be delivered around October 23, 2023.","Rule 14a-8 shareholder proposals must be received by October 23, 2023, at company's Miami Beach office.","Bylaw director nominations and other proposals due by October 23, 2023.","Universal proxy rule notices for non-company nominees also due by October 23, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":23152871.95162476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284238,"accession_number":"0001213900-23-076515","cik":1841330,"company_name":"Pasithea Therapeutics Corp.","ticker":"KTTA","form_type":"8-K","filed_at":"2023-09-14T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Pasithea completes tender offer: buys 5.32M shares at $0.70; post-offer shares 20.8M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 5,323,451 validly tendered shares accepted for purchase at $0.70 per share, no proration.","Tender offer expired Sept 8, 2023; funded from cash on hand.","Post-offer shares outstanding: 20,819,956; CEO notes >8.5M shares repurchased over past 9 months.","CEO: low tender indicates shareholder confidence; buyback provides liquidity and increases remaining holders' ownership."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":23152871.95162476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284237,"accession_number":"0001213900-23-058331","cik":1841330,"company_name":"Pasithea Therapeutics Corp.","ticker":"KTTA","form_type":"8-K","filed_at":"2023-07-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pasithea announces $4M tender offer for common stock at $0.70/share, expected Q3 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized $4.0M tender offer to repurchase up to ~5.7M shares at $0.70 per share in cash.","Tender offer expected to close in the third quarter of 2023.","Executive officers and directors will not tender any shares in the offer.","If oversubscribed, shares will be accepted on a pro rata basis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":23152871.95162476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284236,"accession_number":"0001213900-23-058326","cik":1841330,"company_name":"Pasithea Therapeutics Corp.","ticker":"KTTA","form_type":"8-K","filed_at":"2023-07-20T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Pasithea Therapeutics receives Nasdaq extension to Jan 15, 2024 for bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq granted 180-day extension to January 15, 2024 to regain $1.00 minimum bid price compliance.","Previous non-compliance notice received Jan 19, 2023; extension granted Jul 19, 2023 to Jan 15, 2024.","Company may consider reverse stock split; no assurance of regaining compliance.","Failure to comply by deadline may result in Nasdaq delisting notice; Company can appeal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":23152871.95162476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323584,"accession_number":"0001213900-23-019225","cik":1841330,"company_name":"Pasithea Therapeutics Corp.","ticker":"KTTA","form_type":"8-K","filed_at":"2023-03-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Pasithea Therapeutics confirms no exposure to Silicon Valley Bank","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company holds no deposits or securities at Silicon Valley Bank.","No accounts or any banking relationship with SVB.","Statement issued to clarify lack of exposure amid SVB instability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":23152871.95162476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323583,"accession_number":"0001213900-23-004881","cik":1841330,"company_name":"Pasithea Therapeutics Corp.","ticker":"KTTA","form_type":"8-K","filed_at":"2023-01-24T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Pasithea Therapeutics receives Nasdaq deficiency notice for minimum bid price non-compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Jan 19, 2023 for failure to meet $1.00 minimum bid price rule (Nasdaq 5550(a)(2)).","Company has 180 calendar days, until July 18, 2023, to regain compliance; stock must close at $1.00+ for 10 consecutive days.","If not cured, may request additional 180 days if meeting other listing requirements and intending reverse stock split.","Failure to regain compliance could lead to delisting; company is considering options to cure deficiency.","Receipt of notice does not affect business operations or SEC reporting requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":23152871.95162476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":341579,"accession_number":"0001213900-22-079827","cik":1841330,"company_name":"Pasithea Therapeutics Corp.","ticker":"KTTA","form_type":"8-K","filed_at":"2022-12-14T23:59:59+00:00","items":["1.01","5.07","7.01","9.01"],"status":"ready","headline":"Pasithea settles with Camac Group; to repurchase 3.2M shares at $1.0003, standstill 3 years","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Will buy back 3,205,282 shares (11% of outstanding) at $1.0003 per share (trailing 5-day VWAP).","Reimburses Camac Group expenses up to $689,491; both parties dismiss Delaware litigation with prejudice.","Camac Group enters 3-year standstill, agrees not to engage in proxy contests or change-of-control actions.","Special meeting Dec 9, 2022: all proposals to remove five directors and repeal bylaw changes were denied by shareholders.","Mutual release of claims related to Camac investment, special meeting, and prior acquisitions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":23152871.95162476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":341578,"accession_number":"0001213900-22-063416","cik":1841330,"company_name":"Pasithea Therapeutics Corp.","ticker":"KTTA","form_type":"8-K","filed_at":"2022-10-12T23:59:59+00:00","items":["1.01","2.01","3.02","5.02","7.01","9.01"],"status":"ready","headline":"Pasithea acquires AlloMek for $1.05M cash, 2.7M shares + warrants; adds MEK inhibitor CIP-137401","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total deal value includes $1.05M cash, 2.7M restricted shares, 1M warrants at $1.88, up to $5M milestones, and royalties.","CIP-137401 is a macrocyclic MEK inhibitor for NF1 and Noonan syndrome; already has FDA orphan-drug designation for NF1.","Plans to file IND in 2H 2023 and initiate Phase 1 trial in NF1; expects synergies with existing MS program.","Daniel Schneiderman appointed CFO effective Oct 11, 2022 with base salary $330K and 300K stock options.","Sellers subject to two-year lock-up; 1.35M shares lock up release at one year, then 112.5K monthly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":23152871.95162476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":358520,"accession_number":"0001213900-22-057435","cik":1841330,"company_name":"Pasithea Therapeutics Corp.","ticker":"KTTA","form_type":"8-K","filed_at":"2022-09-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Pasithea Therapeutics appoints Alfred J. Novak to board; two director changes","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Yassine Bendiabdallah resigned from board on Sept 14, 2022, with no disagreement.","Dr. Lawrence Steinman resigned from audit committee, remaining on board and as chair of nominating committee.","Alfred J. Novak appointed to board and audit committee; experienced healthcare executive and former CEO/CFO.","Mr. Novak previously served on boards of Dova Pharmaceuticals (DOVA), LivaNova (LIVN), and others."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":23152871.95162476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":358519,"accession_number":"0001213900-22-051823","cik":1841330,"company_name":"Pasithea Therapeutics Corp.","ticker":"KTTA","form_type":"8-K/A","filed_at":"2022-08-29T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Pasithea Therapeutics files Alpha-5 Integrin financials for acquisition closed June 21, 2022","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Alpha-5 (preclinical-stage, ALS/neuroinflammatory mAbs) had no revenue and $1.7M net loss for FY 2021.","Q1 2022 net loss was $447k; accumulated deficit reached $2.15M as of March 31, 2022.","Total assets $200k, cash & equivalents $122k at March 31, 2022, down from $295k at year-end 2021.","Acquisition closed June 21, 2022; one seller is Pasithea's Executive Chairman and Co-Founder.","Pro forma adjustments deemed immaterial; Alpha-5 became a wholly owned subsidiary of Pasithea."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":23152871.95162476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":377280,"accession_number":"0001213900-22-035226","cik":1841330,"company_name":"Pasithea Therapeutics Corp.","ticker":"KTTA","form_type":"8-K/A","filed_at":"2022-06-27T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Pasithea amends 8-K to extend deadline for Alpha-5 Integrin financials filing","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Original 8-K filed June 22, 2022 reported acquisition of Alpha-5 Integrin, LLC.","This amendment confirms intent to file acquired company financials within 75 days from June 21, 2022.","Pro forma financial information will also be filed within the same period.","No other changes were made to the original Form 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":23152871.95162476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":377283,"accession_number":"0001213900-22-034654","cik":1841330,"company_name":"Pasithea Therapeutics Corp.","ticker":"KTTA","form_type":"8-K","filed_at":"2022-06-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Pasithea Therapeutics shareholders elect directors, ratify Marcum LLP as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected five directors: Tiago Reis Marques, Yassine Bendiabdallah, Lawrence Steinman, Simon Dumesnil, Emer Leahy for one-year terms.","Ratified appointment of Marcum LLP as independent auditor for FY 2022 with 10,751,385 votes for, 1,078,159 against.","Annual Meeting held June 23, 2022; 22,858,371 shares outstanding as of record date May 3, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":23152871.95162476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":377279,"accession_number":"0001213900-22-034884","cik":1841330,"company_name":"Pasithea Therapeutics Corp.","ticker":"KTTA","form_type":"8-K/A","filed_at":"2022-06-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Pasithea Therapeutics reports annual meeting results; all director nominees elected, auditor ratified","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All five director nominees elected: Tiago Reis Marques (5.79M for, 2.07M withheld), Yassine Bendiabdallah, Lawrence Steinman, Simon Dumesnil, Emer Leahy.","Ratification of Marcum LLP as auditor for FY2022 approved with 10.75M for, 1.08M against, 15.6K abstain.","Broker non-votes totaled 3.98M on director elections; no broker non-votes on auditor ratification.","Shareholders present at meeting represented 22.86M shares outstanding as of May 3, 2022 record date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":23152871.95162476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":377282,"accession_number":"0001213900-22-034341","cik":1841330,"company_name":"Pasithea Therapeutics Corp.","ticker":"KTTA","form_type":"8-K","filed_at":"2022-06-22T23:59:59+00:00","items":["1.01","2.01","3.02","7.01","9.01"],"status":"ready","headline":"Pasithea acquires Alpha-5 integrin in $3.75M stock-and-warrant deal for ALS/neurology pipeline","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Pasithea acquires all equity of Alpha-5; total consideration: 3,260,870 shares of KTTA common stock at $1.15/share (11% premium to June 21 close) plus 1M warrants at $1.88 exercise price for 5 years.","Alpha-5 holds preclinical-stage anti-alpha-5 integrin mAb targeting ALS, MS, and other neuroinflammatory disorders; IND filing expected by end of 2023.","Contingent earn-out of 2%–4% of net sales from Alpha-5's drug candidate if commercialized.","Lawrence Steinman, Pasithea's Chairman and co-founder and minority Alpha-5 owner, recused from vote; deal approved by disinterested directors.","Paul B. Manning (Alpha-5 majority owner) will own approximately 10% of Pasithea post-closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":23152871.95162476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":377281,"accession_number":"0001213900-22-032102","cik":1841330,"company_name":"Pasithea Therapeutics Corp.","ticker":"KTTA","form_type":"8-K","filed_at":"2022-06-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Pasithea Therapeutics CFO Stanley Gloss passes away; search for replacement underway","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stanley Gloss, CFO of Pasithea Therapeutics, passed away on June 7, 2022.","Company has commenced a search for a new Chief Financial Officer.","No other officer or board changes were announced in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":23152871.95162476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":414461,"accession_number":"0001213900-21-066518","cik":1841330,"company_name":"Pasithea Therapeutics Corp.","ticker":"KTTA","form_type":"8-K","filed_at":"2021-12-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Pasithea Therapeutics enters new CEO employment agreement with Tiago Reis Marques","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Base salary $450,000; sign-on bonus $100,000 lump sum after Jan 1, 2022.","Annual discretionary bonus up to 75% of base salary.","Equity grants: 200,000 RSUs and 200,000 options vesting over 3 years (33% after 12 months, then quarterly).","Severance: 12 months base salary if terminated without cause, subject to separation agreement.","Agreement effective January 1, 2022; Board approved equity grants on Dec 20, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":23152871.95162476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":414460,"accession_number":"0001213900-21-062398","cik":1841330,"company_name":"Pasithea Therapeutics Corp.","ticker":"KTTA","form_type":"8-K","filed_at":"2021-11-29T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Pasithea Therapeutics prices $30.4M private placement of 8.68M shares and warrants at $3.50/unit.","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds $30.4M from sale of 8.68M shares and accompanying warrants at $3.50 per unit.","Warrants immediately exercisable at $3.50, expire in 5 yrs; cashless exercise and ownership limits apply.","EF Hutton receives 9% cash fee plus 1% non-accountable expense fee and up to $70K accountable expenses.","Proceeds to fund pre-clinical R&D, US/UK clinic businesses, and working capital; resale registration due within 15 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":23152871.95162476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}